What does PHARMACEUTICAL ENTERPRISES BELGIUM do?

PHARMACEUTICAL ENTERPRISES BELGIUM is a wholesaler in Kontich. Public Limited, started on 25 April 1995, 1 establishment.

What is the address of PHARMACEUTICAL ENTERPRISES BELGIUM?

The registered office of PHARMACEUTICAL ENTERPRISES BELGIUM is located at Satenrozen 6A box 2, 2550 Kontich.

Is PHARMACEUTICAL ENTERPRISES BELGIUM still active?

Yes. According to the CBE (17 September 2026) PHARMACEUTICAL ENTERPRISES BELGIUM is active, legal situation “Einde van de opschorting”, started on 25 April 1995.

Is PHARMACEUTICAL ENTERPRISES BELGIUM registered on Peppol?

Yes, PHARMACEUTICAL ENTERPRISES BELGIUM is registered on the Peppol network with ID 0208:0455014924.

What is the enterprise number of PHARMACEUTICAL ENTERPRISES BELGIUM?

The enterprise number of PHARMACEUTICAL ENTERPRISES BELGIUM is BE0455014924.

When was PHARMACEUTICAL ENTERPRISES BELGIUM founded?

PHARMACEUTICAL ENTERPRISES BELGIUM was founded on 25 April 1995.

Who are the directors of PHARMACEUTICAL ENTERPRISES BELGIUM?

According to the 2025 annual accounts, the directors of PHARMACEUTICAL ENTERPRISES BELGIUM are: A-Pop Management CommV, Swolfs Consultancy BV.

Is PHARMACEUTICAL ENTERPRISES BELGIUM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 April 1995; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMACEUTICAL ENTERPRISES BELGIUM make in 2025?

PHARMACEUTICAL ENTERPRISES BELGIUM recorded a loss after taxes of € 96,338 in financial year 2025.

What is the revenue of PHARMACEUTICAL ENTERPRISES BELGIUM?

As a small company, PHARMACEUTICAL ENTERPRISES BELGIUM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 53,524.

How much does an employee at PHARMACEUTICAL ENTERPRISES BELGIUM earn?

The average wage cost per full-time employee at PHARMACEUTICAL ENTERPRISES BELGIUM was € 88,500 in 2022: staff costs of € 88,515 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMACEUTICAL ENTERPRISES BELGIUM have?

According to the 2025 annual accounts, PHARMACEUTICAL ENTERPRISES BELGIUM has 0.8 full-time equivalents (FTE).

PHARMACEUTICAL ENTERPRISES BELGIUM (Public Limited)

Dossier PHARMACEUTICAL ENTERPRISES BELGIUM, printed on 17 September 2026 from databakkes.be/en/0455014924/pharmaceutical-enterprises-belgium. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Figures corrected NBB

Corrected annual account filed for 2022.
Busy address KBO

13 other companies have their registered office at the same address; threshold 10.
Legal situation KBO

Einde van de opschorting according to the CBE.

Financials

Financial year 2025

PHARMACEUTICAL ENTERPRISES BELGIUM from Kontich, company number BE0455014924, closed financial year 2025 with a result of € -96,338 after tax. For that financial year PHARMACEUTICAL ENTERPRISES BELGIUM recorded a gross margin of € 53,524 and equity of € 69,896. Compared with financial year 2024, the result moved from € -11,191 to € -96,338. The company made a loss. The buffer shrank hard: equity is 58 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.

What it is worth Shrank hard

€ 69,896

▼ 58% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -96,338

▼ 761 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 19,262

▼ 57% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -262,876.

People and assets in 2025

Full-time equivalents

0.8

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 86,626

▲ 12% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,933

▼ 31% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 15,734

▼ 96% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 16,861

▲ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 210,245 Gross margin 2022: € 210,245 First fiscal year in the series	€ 145,648 Gross margin 2023: € 145,648 ▼ 31% vs 2022 (€ 210,245) Unfavourable step	€ 131,990 Gross margin 2024: € 131,990 ▼ 9% vs 2023 (€ 145,648) Unfavourable step	€ 53,524 Gross margin 2025: € 53,524 ▼ 59% vs 2024 (€ 131,990) Unfavourable step	▼ 59%
Profit after taxes	€ 50,396 Profit after taxes 2022: € 50,396 First fiscal year in the series	€ 11,567 Profit after taxes 2023: € 11,567 ▼ 77% vs 2022 (€ 50,396) Unfavourable step	€ -11,191 Profit after taxes 2024: € -11,191 ▼ € 22,758 vs 2023 (€ 11,567) Unfavourable step	€ -96,338 Profit after taxes 2025: € -96,338 ▼ € 85,147 vs 2024 (€ -11,191) Unfavourable step	▼ € 85,147
Equity	€ 168,417 Equity 2022: € 168,417 First fiscal year in the series	€ 177,425 Equity 2023: € 177,425 ▲ 5% vs 2022 (€ 168,417) Favourable step	€ 166,234 Equity 2024: € 166,234 ▼ 6% vs 2023 (€ 177,425) Unfavourable step	€ 69,896 Equity 2025: € 69,896 ▼ 58% vs 2024 (€ 166,234) Unfavourable step	▼ 58%
Total debts	€ 538,845 Total debts 2022: € 538,845 First fiscal year in the series	€ 1,078,603 Total debts 2023: € 1,078,603 ▲ 100% vs 2022 (€ 538,845) Unfavourable step	€ 455,284 Total debts 2024: € 455,284 ▼ 58% vs 2023 (€ 1,078,603) Favourable step	€ 32,595 Total debts 2025: € 32,595 ▼ 93% vs 2024 (€ 455,284) Favourable step	▼ 93%
Cash	€ 8,060 Cash 2022: € 8,060 First fiscal year in the series	€ 498,915 Cash 2023: € 498,915 ▲ € 490,855 vs 2022 (€ 8,060) Favourable step	€ 44,815 Cash 2024: € 44,815 ▼ 91% vs 2023 (€ 498,915) Unfavourable step	€ 19,262 Cash 2025: € 19,262 ▼ 57% vs 2024 (€ 44,815) Unfavourable step	▼ 57%
Land & buildings	€ 79,374 Land & buildings 2022: € 79,374 First fiscal year in the series	€ 67,162 Land & buildings 2023: € 67,162 ▼ 15% vs 2022 (€ 79,374) Unchanged	€ 54,951 Land & buildings 2024: € 54,951 ▼ 18% vs 2023 (€ 67,162) Unchanged	€ 42,739 Land & buildings 2025: € 42,739 ▼ 22% vs 2024 (€ 54,951) Unchanged	▼ 22%
Retained profit	€ -164,355 Retained profit 2022: € -164,355 First fiscal year in the series	€ -155,348 Retained profit 2023: € -155,348 ▲ € 9,007 vs 2022 (€ -164,355) Favourable step	€ -166,539 Retained profit 2024: € -166,539 ▼ € 11,191 vs 2023 (€ -155,348) Unfavourable step	€ -262,876 Retained profit 2025: € -262,876 ▼ € 96,338 vs 2024 (€ -166,539) Unfavourable step	▼ € 96,338
Balance sheet total	€ 707,262 Balance sheet total 2022: € 707,262 First fiscal year in the series	€ 1,256,028 Balance sheet total 2023: € 1,256,028 ▲ 78% vs 2022 (€ 707,262) Unchanged	€ 621,518 Balance sheet total 2024: € 621,518 ▼ 51% vs 2023 (€ 1,256,028) Unchanged	€ 102,491 Balance sheet total 2025: € 102,491 ▼ 84% vs 2024 (€ 621,518) Unchanged	▼ 84%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	0.8 Employees (FTE) 2023: 0.8 ▼ 0.2 vs 2022 (1) Unchanged	0.8 Employees (FTE) 2024: 0.8 Unchanged (0.8) Unchanged	0.8 Employees (FTE) 2025: 0.8 Unchanged (0.8) Unchanged

Key figures of PHARMACEUTICAL ENTERPRISES BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACEUTICAL ENTERPRISES BELGIUM?

What happened at PHARMACEUTICAL ENTERPRISES BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 29, 2026 New annual accounts for financial year 2025: loss of € 96,338. Source: NBB ↗
2020 A-Pop Management CommV became a director. NBB
2020 Swolfs Consultancy BV became a director. NBB
May 16, 1995 New establishment in Kontich. KBO
Apr 25, 1995 Start of the company according to the CBE. KBO

In short

From € 50,396 profit in 2022 to € 96,338 loss in 2025.

Paid € 24,557 in corporate taxes since 2022.

Best year ever: 2022, with € 50,396 profit.

On average € 210,200 of value added per employee in 2022.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMACEUTICAL ENTERPRISES BELGIUM? We notify you, reason included.

Follow PHARMACEUTICAL ENTERPRISES BELGIUM

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

A-Pop Management CommV Swolfs Consultancy BV

GLOBIPHARM

GLOBIFER INTL

PHARMACEUTICAL ENTERPRISES BELGIUM

Behind PHARMACEUTICAL ENTERPRISES BELGIUM are A-Pop Management CommV and Swolfs Consultancy BV. The same people are also behind GLOBIPHARM. A-Pop Management CommV is also behind GLOBIFER INTL.

See the full network in the app

Directors

According to the 2025 annual accounts

A-Pop Management CommV

Director · represented by Popowski Anthony

Also active at: GLOBIPHARM, GLOBIFER INTL

since 2020

Swolfs Consultancy BV

Managing director · represented by Swolfs Patrick

Also active at: GLOBIPHARM

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Satenrozen 6A box 2

2550 Kontich

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.

All companies at this address →

CADIS

€ 986,725 gross margin · 2025

Straalstudio

Schilderstudio

€ 887,895 gross margin · 2025

BJ BTW EENHEID

Project Nekton

€ 486,955 gross margin · 2025

+8 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0455.014.924

VAT number

BE 0455.014.924

Registered office

Satenrozen 6A bus 2, 2550 Kontich

Names & denominations

PHARMACEUTICAL ENTERPRISES BELGIUM · Phare Belgium

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Einde van de opschorting

Start date

25 April 1995

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗